JWH-193

JWH-193 is a drug from the aminoalkylindole and naphthoylindole families which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has a binding affinity at the CB₁ receptor of 6 nM, binding around seven times more tightly than the parent compound JWH-200,^[1] though with closer to twice the potency of JWH-200 in activity tests.

JWH-193

Legal status
Legal status	CA: Schedule II DE: NpSG (Industrial and scientific use only) UK: Class B US: Schedule I
Identifiers
IUPAC name (1-(2-Morpholin-4-ylethyl)indol-3-yl)-4-methylnaphthalen-1-ylmethanone
CAS Number	133438-58-1 Y
PubChem CID	10250276
ChemSpider	8425762
UNII	WB1TIJ1IO9
CompTox Dashboard (EPA)	DTXSID70158108
Chemical and physical data
Formula	C26H26N2O2
Molar mass	398.506 g·mol−1
3D model (JSmol)	Interactive image
SMILES c3cccc1c3c(ccc1C)C(=O)c5c2ccccc2n(c5)CCN4CCOCC4
InChI InChI=1S/C26H26N2O2/c1-19-10-11-23(21-7-3-2-6-20(19)21)26(29)24-18-28(25-9-5-4-8-22(24)25)13-12-27-14-16-30-17-15-27/h2-11,18H,12-17H2,1H3 Key:ICKWPPYMDARCKJ-UHFFFAOYSA-N
(verify)

In the United States, all CB₁ receptor agonists of the 3-(1-naphthoyl)indole class such as JWH-193 are Schedule I Controlled Substances.^[2]

Related compounds

A structural isomer of JWH-193 with the methyl group on the indole ring instead of the naphthoyl ring, was also found to be of similarly increased potency over JWH-200.^[3][4]

6-Methyl-JWH-200

See also

• JWH-122
• JWH-198